Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009143 | 1.00 | CRBN (0.49) | CRBNDDB1GPR119EPHX2KDM1A | |
| SCHEMBL27148853 | 0.95 | CRBN (0.46) | CRBNDDB1GPR119EPHX2KDM1A | |
| SCHEMBL23173797 | 0.91 | CRBN (0.56) | CRBNDDB1GPR119EPHX2USP30 | |
| SCHEMBL23134050 | 0.89 | CRBN (0.42) | CRBNDDB1GPR119EPHX2KDM1A | |
| SCHEMBL30392744 | 0.88 | CRBN (0.51) | CRBNDDB1EPHX2USP30 | |
| SCHEMBL28783614 | 0.86 | DDB1 (0.47) | CRBNDDB1KDM4EMAPT | |
| SCHEMBL23121669 | 0.85 | DDB1 (0.46) | CRBNDDB1 | |
| SCHEMBL23134742 | 0.85 | DDB1 (0.44) | CRBNDDB1 | |
| SCHEMBL23133973 | 0.85 | DDB1 (0.44) | CRBNDDB1 | |
| Hydrochloric Acid SCHEMBL23122759 | 0.85 | DDB1 (0.46) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | BRD9, BRD2, BRD1 | CRBN 850/4885DDB1 1555/4885GPR119 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.